Mostra i principali dati dell'item
Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers
| dc.creator | Triposkiadis F., Xanthopoulos A., Parissis J., Butler J., Farmakis D. | en |
| dc.date.accessioned | 2023-01-31T10:10:22Z | |
| dc.date.available | 2023-01-31T10:10:22Z | |
| dc.date.issued | 2022 | |
| dc.identifier | 10.1007/s10741-020-09987-z | |
| dc.identifier.issn | 13824147 | |
| dc.identifier.uri | http://hdl.handle.net/11615/79796 | |
| dc.description.abstract | Chronic heart failure (HF) is rare in the young and common in the elderly in the Western world. HF in the young is usually due to specific causes, predominantly or exclusively affecting the heart (adult congenital heart disease, different types of cardiomyopathies, myocarditis, or cardiotoxicity). In contrast, the mechanisms underlying HF development in the elderly have not been completely delineated. We propose that in most elderly patients, HF, regardless of the left ventricular ejection fraction (LVEF), is the consequence of the acceleration of cardiovascular aging by specific risk factors (usually hypertension, obesity, type 2 diabetes mellitus [T2DM], coronary artery disease [CAD], and valvular heart disease [VHD]), most affecting both the heart and the vasculature. These risk factors act individually or more commonly in groups, directly or indirectly (hypertension, obesity, and T2DM may lead to HF through an intervening myocardial infarction). The eventual HF phenotype and outcomes in the elderly are additionally dependent on the presence and/or development of comorbidities (atrial fibrillation, anemia, depression, kidney disease, pulmonary disease, sleep disordered breathing, other) and disease modifiers (race, sex, genes, other). The clinical implications of this paradigm are that aggressive treatment of hypertension, obesity, T2DM (preferably with metformin and sodium-glucose cotransporter-2 inhibitors), CAD, and VHD on top of measures that retard cardiovascular aging are the steadfast underpinning for HF prevention in the elderly, which represent the vast majority of HF patients. © 2020, Springer Science+Business Media, LLC, part of Springer Nature. | en |
| dc.language.iso | en | en |
| dc.source | Heart Failure Reviews | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086332435&doi=10.1007%2fs10741-020-09987-z&partnerID=40&md5=0b57f9d0c48ac0e89e4ee7f5b5cacd79 | |
| dc.subject | metformin | en |
| dc.subject | sodium glucose cotransporter 2 inhibitor | en |
| dc.subject | aging | en |
| dc.subject | anemia | en |
| dc.subject | atrial fibrillation | en |
| dc.subject | cardiovascular aging | en |
| dc.subject | cell aging | en |
| dc.subject | clinical outcome | en |
| dc.subject | comorbidity | en |
| dc.subject | coronary artery disease | en |
| dc.subject | depression | en |
| dc.subject | disease association | en |
| dc.subject | disease burden | en |
| dc.subject | disease exacerbation | en |
| dc.subject | global health | en |
| dc.subject | heart failure | en |
| dc.subject | heart infarction | en |
| dc.subject | heart left ventricle ejection fraction | en |
| dc.subject | heredity | en |
| dc.subject | human | en |
| dc.subject | hypertension | en |
| dc.subject | kidney disease | en |
| dc.subject | lung disease | en |
| dc.subject | morbidity | en |
| dc.subject | mortality | en |
| dc.subject | non insulin dependent diabetes mellitus | en |
| dc.subject | obesity | en |
| dc.subject | pathogenesis | en |
| dc.subject | phenotype | en |
| dc.subject | prevalence | en |
| dc.subject | quality of life | en |
| dc.subject | race | en |
| dc.subject | Review | en |
| dc.subject | risk factor | en |
| dc.subject | sex | en |
| dc.subject | sleep disordered breathing | en |
| dc.subject | valvular heart disease | en |
| dc.subject | adult | en |
| dc.subject | aged | en |
| dc.subject | congenital heart malformation | en |
| dc.subject | heart failure | en |
| dc.subject | heart left ventricle function | en |
| dc.subject | heart stroke volume | en |
| dc.subject | non insulin dependent diabetes mellitus | en |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Aging | en |
| dc.subject | Diabetes Mellitus, Type 2 | en |
| dc.subject | Heart Defects, Congenital | en |
| dc.subject | Heart Failure | en |
| dc.subject | Humans | en |
| dc.subject | Risk Factors | en |
| dc.subject | Sodium-Glucose Transporter 2 Inhibitors | en |
| dc.subject | Stroke Volume | en |
| dc.subject | Ventricular Function, Left | en |
| dc.subject | Springer | en |
| dc.title | Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers | en |
| dc.type | other | en |
Files in questo item
| Files | Dimensione | Formato | Mostra |
|---|---|---|---|
|
Nessun files in questo item. |
|||